Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
about
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsPragmatic medicine in solid cancer: a translational alternative to precision medicinePlatelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib.Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access ProgramUK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelinesA multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.Gastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts.Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials.State of the Art in the Treatment of Gastrointestinal Stromal Tumors.Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious.Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor.Update on Gastrointestinal Stromal Tumors for Radiologists.Controversies in the management of gastrointestinal stromal tumors.Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations.Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.Get the GIST? An overview of gastrointestinal stromal tumours.Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature reviewRegorafenib in gastrointestinal stromal tumors.Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.Recent advances in managing gastrointestinal stromal tumor.Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.A systematic review and network meta-analysis of post-imatinib therapy in advanced gastrointestinal stromal tumour.Emerging drugs for the treatment of gastrointestinal stromal tumour.Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience.CCDC26 knockdown enhances resistance of gastrointestinal stromal tumor cells to imatinib by interacting with c-KIT.Management of hemorrhage in gastrointestinal stromal tumors: a review.Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications.
P2860
Q26799387-87B112D2-78A4-452C-9AEB-0A63213B05B3Q28391863-EB711222-E800-4B4B-B9EC-DE65BAAF084FQ30250273-128CACDD-5C44-49D0-BC9E-163DFB75652CQ33433902-11DF6FA3-8CD6-48FF-97C2-0A9037E9B872Q33567889-35D75FC3-1BCE-46FB-8A31-D24799D1A4C3Q33584090-92D8D0CA-6B02-4BC6-856A-81905DB22984Q33612778-8AC41C6E-BA91-478D-9B30-72299A4A6707Q34662893-953DBC3D-976D-4F61-A3DF-D149F2386194Q34662946-AA3F9FE8-CDA7-4F14-8D93-E524C5452473Q34672344-0DCD41D9-8301-4A0E-A60E-31C646DCC2A8Q34737119-8A0DAF07-32EE-4895-9D28-E894AB52424AQ35679349-C378213D-8EEF-491B-95D3-78773F2D7CB9Q35820539-17A32A9A-5C77-4A88-BF87-B4D553B4344EQ36192000-171E9F2C-1E80-4D6E-A323-A9D8E023DFA0Q36344557-2AEB8B54-02E7-44AE-B18A-31AE34714AE8Q37131708-20FC31BE-09E6-4173-BDEA-47CF0495B3B1Q37367438-3AE64138-B05D-4037-BC70-E7DB9FA5EA52Q37589533-D671AAF4-03AA-4BB7-B81B-4A72E5BB0C6EQ38199797-449D772B-AEE3-4851-9E8C-A3A00E1C6B94Q38233339-B6F7B7DF-74AF-4CB7-84E3-7C00A39E5D7BQ38268000-65EA4A74-8FC4-42DB-B693-A99899D6B667Q38268165-EE0C97F7-6DEF-4C69-A8C9-F62928B4E529Q38496239-D3DC980D-7A4C-4167-A98C-85A4D773BA61Q38527941-C65E1049-C1A5-40B3-9892-69C0DDC47230Q38718860-C545B8D9-8063-4E86-9589-7BDACB419F36Q38865460-D92D4A13-6821-41A8-ABF4-9B980577B7ADQ38925022-98A672F8-0771-4A0B-A15C-2AB0D364FA29Q38971422-273F2E80-8A88-462A-9EF4-C9D6F1FFA39AQ39141806-65A8A6B5-939B-42BF-9E05-754244032778Q40567012-C3A31F24-54C4-4AD9-A097-225B21E0C4CAQ41725812-FA20B2DA-B6C1-4F6A-B914-BEDD2EBFBEB6Q41735562-A83E2CCA-56A0-4624-AE2E-43BEBF923391Q47114063-E2C26E16-E2E2-455C-A829-8D00919F15C0Q47160941-EED745AF-6647-43E4-BE32-D7063D4B9970Q47355982-152445C6-31EB-416A-8410-6C4AE87679ACQ47681377-86EEA79D-3920-4BA6-B32B-7065A5C3565FQ48128508-EA37A6F4-117E-4E8D-A2E8-BCBC7A1FCD4FQ49248913-20198BBB-19DD-4923-B79B-39DA98F61D42Q52562706-47E0DBE1-8358-42BE-A6FF-F7264872061AQ53366505-22B5071A-C164-4E9F-A974-2C02C898E01E
P2860
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Resumption of imatinib to cont ...... ebo-controlled, phase 3 trial.
@ast
Resumption of imatinib to cont ...... ebo-controlled, phase 3 trial.
@en
Resumption of imatinib to cont ...... ebo-controlled, phase 3 trial.
@nl
type
label
Resumption of imatinib to cont ...... ebo-controlled, phase 3 trial.
@ast
Resumption of imatinib to cont ...... ebo-controlled, phase 3 trial.
@en
Resumption of imatinib to cont ...... ebo-controlled, phase 3 trial.
@nl
prefLabel
Resumption of imatinib to cont ...... ebo-controlled, phase 3 trial.
@ast
Resumption of imatinib to cont ...... ebo-controlled, phase 3 trial.
@en
Resumption of imatinib to cont ...... ebo-controlled, phase 3 trial.
@nl
P2093
P2860
P1433
P1476
Resumption of imatinib to cont ...... ebo-controlled, phase 3 trial.
@en
P2093
Baek-Yeol Ryoo
Byung-Ho Nam
Changhoon Yoo
George D Demetri
Hyun Jin Kim
Jong Jin Lee
Jyothi Jagannathan
Min-Hee Ryu
Nikhil Ramaiya
Yoon-Koo Kang
P2860
P304
P356
10.1016/S1470-2045(13)70453-4
P577
2013-10-18T00:00:00Z